In Aerosol, Fine Spray, Effervescent, Pressurized Fluid, Vapor Or Gas, Or Complete Composition Therefor Patents (Class 424/1.13)
-
Patent number: 11232696Abstract: Concealed mark preparation with core-shell luminosphores for customs security check system and application thereof, to address that infrared luminescent materials have not been used in senseless customs clearance field, absorption cross sections of infrared luminescent materials currently available are not big enough, and upconversion luminescence intensity thereof is low, consequently, the luminescent marks are not clear enough to recognize marked abnormal luggage, and provide a following solution: step 1: preparing TiQ2; step 2: preparing Ag@TiO2 composite nanoparticles; step 3: preparing Ag@TiQ2@NaYF4:Yb3+, Er3+ luminescent nanoparticles; step 4: making concealed luggage marks.Type: GrantFiled: July 30, 2021Date of Patent: January 25, 2022Assignees: JINLING HAIGUAN TECHNICAL CENTER, JIANGSU YANGTZE TESTING AND CERTIFICATION CO., LTD.Inventors: Ying Hong, Rong Gao, Jinling Wang, Guosong Chen, Yuanyuan Zhu, Jing Fang, Ling Gao, Weijian Shen, Wei An, Jiansong Chen
-
Patent number: 10206873Abstract: Methods of making a dry powder, comprise (a) delivering a liquid solution or suspension and a second, immiscible fluid to a flow path, (b) transporting the liquid solution or suspension and the immiscible fluid along the flow path, wherein the flow path includes two or more flow passages of different diameters, at least one flow divider which divides and diverts the flowing mixture into at least two separate passages, wherein the separate passages subsequently intersect to combine their respective flows into a single flowing stream, (c) rapidly reducing the pressure of the single flowing stream, whereby droplets are formed, and (d) passing the droplets through a flow of inert drying gas to form a dry powder. A nebulizing nozzle includes an inlet, a flow path as described, and a restrictor nozzle outlet.Type: GrantFiled: August 4, 2017Date of Patent: February 19, 2019Assignee: COLORADO CAN LLCInventors: Xuno Gildelamadrid, Robert E. Sievers
-
Patent number: 9542861Abstract: Medical training kits and methods include a simulated liquid blood which simulates mammalian whole blood and a simulated hemostatic component. The simulated liquid blood includes a gellable component, and a simulated hemostatic component includes a gelling agent. The gelling agent causes the gellable component in the simulated liquid blood to form a mass of semi-solid or solid material in response the simulated blood being brought into contact therewith to thereby simulate blood clotting. In certain embodiments, the gellable component is chitosan and/or an alginate compound and the gelling agent is at least one compound which causes the gellable component to desolubulize, polymerize, complex, precipitate, cross-link and the like so as to form a semi-solid or solid mass of chitosan in response to physical contact between the simulated blood and the simulated hemostatic agent.Type: GrantFiled: February 22, 2013Date of Patent: January 10, 2017Assignee: LUNA INNOVATIONS INCORPORATEDInventors: Bradford L. Day, Michael J. Danilich
-
Patent number: 9417241Abstract: Presented is a kit containing TCPP for use in prognosing a patient's response to a cancer therapy wherein prior to the therapy contacting a sample of cells from the patient's tissue or organ being treated for the cancer with a solution of TCPP to permit binding of the TCPP to components of the abnormal dysplastic or carcinomic cells, if any are present; detecting TCPP fluorescence in the sample, the presence of TCPP fluorescence being indicative that the sample contains dysplastic or carcinomic cells; at intervals during the therapy and subsequent to the therapy performing steps a-c on another sample of cells from the patient's tissue or organ being treated for the cancer; and determining if the percentage of abnormal pre-cancerous cells in the samples tested during and subsequent to the therapy are reduced as compared with the sample tested prior to the therapy, the reduction being prognostic of the patients response to the cancer therapy.Type: GrantFiled: March 10, 2015Date of Patent: August 16, 2016Assignee: BIOAFFINITY TECHNOLOGIES, INC.Inventor: Jeffrey Garwin
-
Patent number: 9393260Abstract: Exopolysaccharide of a bacterial strain for its use in treatment and/or care of the skin, mucous membranes, hair and/or nails, as well as its cosmetic and/or dermopharmaceutical compositions. In particular, for the aging of skin and in particular for the treatment and/or prevention of wrinkles.Type: GrantFiled: March 22, 2013Date of Patent: July 19, 2016Assignees: Lubrizol Advanced Materials, Inc., Polymaris BiotechnologyInventors: Raquel Delgado González, Albert Soley Astals, Anthony Courtois, Bertrand Thollas
-
Patent number: 9028806Abstract: The present invention relates to a batch method for impregnating a nonporous polymer pharmaceutical carrier with an active substance, characterized in that said method includes the following consecutive steps: a) mixing the active substance and the nonporous polymer pharmaceutical carrier, the pharmaceutical carrier being in a solid form and insoluble in supercritical CO2 and not being non-crosslinked polyvinylpyrrolidone; b) performing a step of molecular diffusion in the absence of water by contacting, in a static mode without agitation, the mixture obtained in step a) with supercritical CO2 at a pressure of 80 to 170 bars, at a temperature of 31 to 90° C. for 1 to 6 hours; c) recovering the polymer pharmaceutical carrier impregnated with the active substance obtained in step b), the impregnated pharmaceutical carrier being nonporous and being in a solid form and the active substance being in an amorphous form, the method being implemented in the absence of an additional solvent.Type: GrantFiled: May 12, 2010Date of Patent: May 12, 2015Assignee: Pierre Fabre MedicamentInventors: Hubert Lochard, Bernard Freiss
-
Patent number: 8974828Abstract: Methods of treating atrial arrhythmia include administering an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof, such that the at least one antiarrhythmic pharmaceutical agent first enters the heart through the pulmonary vein to the left atrium. Other methods of treating atrial arrhythmia include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. An amount of the at least one antiarrhythmic pharmaceutical agent may peak in the coronary sinus of the heart at a time ranging from 10 seconds to 30 minutes from initiation of the administering. Unit doses, aerosols, and kits are also contemplated.Type: GrantFiled: March 18, 2010Date of Patent: March 10, 2015Assignee: InCarda Therapeutics, Inc.Inventors: Carlos A. Schuler, Rangachari Narasimhan
-
Patent number: 8968760Abstract: A method for attaching an implant to tissue is disclosed. In embodiments, a method includes applying a sprayable material to tissue, the sprayable material possessing functional groups capable of binding to tissue. The sprayable material also possesses functional groups capable of binding to an implant. In embodiments, the functional groups capable of binding to an implant include nucleotides. In such a case, the implant possesses complementary nucleotides capable of binding to the nucleotides on the sprayable material, thereby permitting hydrogen binding between the two. The implant may thus be affixed to tissue, and repositioned as necessary, prior to more permanent attachment utilizing means such as sutures, tacks, etc.Type: GrantFiled: February 24, 2012Date of Patent: March 3, 2015Assignee: Covidien LPInventors: Timothy Sargeant, Jonathan Thomas
-
Patent number: 8940271Abstract: The invention includes compositions for transmucosal administration to an animal comprising at least one active agent and a pharmaceutically acceptable carrier. A preferred active agent is selected from the group consisting of meloxicam, carprofen, enrofloxacin, clemastine, diphenhydramine, digoxin, levothyroxine, cyclosporine, ondansetron, lysine, zolpidem, propofol, nitenpyram, ivermectin, milbemycin, and pharmaceutically acceptable salts, solvates and esters thereof. In another embodiment, the invention includes methods of treating or preventing a condition in an animal comprising transmucosally administering a composition comprising a therapeutically or prophylactically effective amount of an active agent and a pharmaceutically acceptable carrier.Type: GrantFiled: December 15, 2011Date of Patent: January 27, 2015Assignee: Abbott LaboratoriesInventors: Mark C. Heit, Antonio M. Benitz, Dennis F. Steadman, David M. Petrick
-
Patent number: 8889099Abstract: Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal one or more impurities, from the peptide or protein. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting for example in a rapid increase in blood agent concentration. The formulations include microparticles formed of (i) the active agent, which may be charged or neutral, and (ii) a transport enhancer that masks the charge of the agent and/or that forms hydrogen bonds with the target biological membrane in order to facilitate transport. In one embodiment, insulin is administered via the pulmonary delivery of microparticles comprising fumaryl diketopiperazine and insulin in its biologically active form. This method of delivering insulin results in a rapid increase in blood insulin concentration that is comparable to the increase resulting from intravenous delivery.Type: GrantFiled: January 30, 2013Date of Patent: November 18, 2014Assignee: MannKind CorporationInventors: Solomon S. Steiner, Rodney J. Woods, Joseph W. Sulner
-
Patent number: 8858917Abstract: Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as vital infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be a surfactant and, optionally, a carrier. The formulation may be administered as a powder where the particles consist basically of the material altering surface tension. The carrier may be a solution, such as an alcohol, although an aqueous solution may be utilized, or a material mixed with the material altering surface tension to form particles.Type: GrantFiled: January 9, 2009Date of Patent: October 14, 2014Assignee: President and Fellows of Harvard CollegeInventors: David A. Edwards, Howard A. Stone
-
Patent number: 8668899Abstract: A sprayable polymeric foam hemostat for both compressible and non-compressible (intracavitary) acute wounds is disclosed. The foam comprises hydrophobically-modified polymers, such as hm-chitosan, or other amphiphilic polymers that anchor themselves within the membrane of cells in the vicinity of the wound. By rapidly expanding upon being released from a canister pressurized with liquefied gas propellant, the foam is able to enter injured body cavities and staunch bleeding. The seal created is strong enough to substantially prevent the loss of blood from these cavities. Hydrophobically-modified polymers inherently prevent microbial infections and are suitable for oxygen transfer required during normal wound metabolism. The amphiphilic polymers form solid gel networks with blood cells to create a physical clotting mechanism that prevent loss of blood.Type: GrantFiled: November 15, 2010Date of Patent: March 11, 2014Assignee: University of Maryland, College ParkInventors: Matthew Dowling, Srinivasa Raghavan
-
Patent number: 8609120Abstract: An ozone delivery system, method, and apparatus are disclosed. Ozonated water can be used to disinfect and clean various surfaces, equipment, and animals in a dairy setting. Animals can be disinfected and protected from disease through the use of wash-pen and sprayer injections, and other footbath products. Ozone can be educted into a drop hose and a pre-dip line at periodic intervals and into a foot bath to provide refreshed ozonated water. The ozone delivery system and method sterilizes all equipment and floor surfaces without damaging diary equipment components. The system can incorporate computer-controlled options such as maintaining off gas levels, maintaining cleaning and disinfecting records, monitoring ozonated water levels, monitoring concentrations of ozone in said ozonated water, controlling entry and exit gates, controlling a drainage system, and monitoring and educting ozone in a foot bath and wash pen.Type: GrantFiled: July 15, 2011Date of Patent: December 17, 2013Inventor: Dana Heacox
-
Patent number: 8609043Abstract: The present invention relates to the use of a container, made of an inorganic additive containing plastic material, for reducing physical/chemical interaction between the container and an oil, fat and/or wax containing formulation contained therein.Type: GrantFiled: August 6, 2012Date of Patent: December 17, 2013Assignee: M & P Patent AktiengesellschaftInventor: Claudia Mattern
-
Patent number: 8586066Abstract: A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content less than 25%. In addition, a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis is provided, and includes applying to the affected area of patient requiring such treatment an antifungal composition.Type: GrantFiled: June 21, 2011Date of Patent: November 19, 2013Assignee: Delcor Asset CorporationInventors: Greg Davey, Albert Zorko Abram
-
Patent number: 8568688Abstract: An aerosol for disinsectization comprising a mixture comprising a disinfestant component, a solvent, and a propellant, and a pressure-resistant container provided with an actuator, wherein the mixture is contained in the pressure-resistant container, and wherein the solvent is contained in the mixture in an amount of from 0 to 10% by volume, and the actuator has an orifice diameter of from 0.7 to 2 mm; and an aerosol for disinsectization comprising a mixture comprising a disinfestant component, a solvent, and a propellant, and a pressure-resistant container provided with an actuator, wherein the mixture is contained in the pressure-resistant container, and wherein the solvent is contained in the mixture in an amount of from 0 to 10% by volume, and the actuator has a long nozzle having an orifice diameter of from 0.4 to 2 mm.Type: GrantFiled: August 4, 2004Date of Patent: October 29, 2013Assignee: Fumakilla LimitedInventors: Shingo Fujii, Miho Iduhara, Shigeki Takaki, Masaaki Sugiura, Kazuyuki Ikeda
-
Publication number: 20130136688Abstract: The present invention concerns a delivery system administered to the lung preferably by inhalation comprising a polymer-based nanoparticle; and a linker comprising a first portion non-covalently anchored to said nanoparticle, wherein at least part of said first portion comprises a hydrophobic/lipophilic segment embedded in said nanoparticle; and a second portion comprising a coupling group, preferably a maleimide compound, exposed at the outer surface of said nanoparticle. In accordance with one embodiment, the delivery system comprises one or more targeting agents, each covalently bound to said coupling group, preferably maleimide compound, and is administered as an aerosol in the therapy or diagnosis of lung cancer or bronchial dysplasia. In accordance with yet another embodiment, the delivery system comprises a drug and/or a radiopharmaceutical and/or a contrasting agent. A specific example for a linker in accordance with the invention is octadecyl-4-(maleimideomethyl)cyclohexane-carboxylic amide (OMCCA).Type: ApplicationFiled: November 28, 2012Publication date: May 30, 2013Inventors: Jürgen Borlak, Shimon Benita, Nir Debotton, Nour Karra, Oshrat Harush-Frenkel
-
Patent number: 8398961Abstract: The present invention relates to agents for the setting and styling of keratin fibers, in particular human hair, from a suitable dispenser system in the form of a fine powder, which is optionally freshly ground, shaved or rasped only directly prior to use, and to the use of this preparation for the treatment of keratin fibers, in particular human hair.Type: GrantFiled: June 17, 2008Date of Patent: March 19, 2013Assignee: Henkel AG & Co. KGaAInventors: Anett (née Sälzer) Kaplan, Bernd Richters
-
Patent number: 8048844Abstract: Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.Type: GrantFiled: February 7, 2003Date of Patent: November 1, 2011Assignee: The Regents of the University of CaliforniaInventors: Jay A. Nadel, Kiyoshi Takeyama
-
Patent number: 8026238Abstract: A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content of less than 25%. In addition, a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis is provided, and includes applying to the affected area of a patient requiring such treatment an antifungal composition.Type: GrantFiled: December 2, 2008Date of Patent: September 27, 2011Assignee: Stiefel Research Australia, Pty LtdInventors: Greg Davey, Albert Zorko Abram
-
Patent number: 8003075Abstract: The present invention includes a diagnostic assay for the detection and determination of MGP in a human serum sample, which comprises the use of one or more antibodies, preferably monoclonal antibodies, specifically recognizing epitopes on and/or conformations of human Matrix Gla-Protein. A method is provided for using MGP-related antigens as biomarkers for certain diseases, for example, atherosclerosis and other vascular diseases, and angiogenesis/neogenesis in tumor development. Monoclonal antibodies of class IgG are described for use in the assay, which are defined herein as mAb3-15, mAb35-49[Glu], mAb35-49[Gla], mAb35-53[Glu], and mAb35-53[Gla]. Polyclonal antibodies and methods are also disclosed for measuring MGP in a human serum sample.Type: GrantFiled: April 20, 2010Date of Patent: August 23, 2011Assignee: MGP Diagnostics A/SInventor: Cees Vermeer
-
Publication number: 20110135569Abstract: Methods are provided for the local radiotherapy of cancers such as locally invasive, advanced stage solid tumors, and normal tissues penetrated by processes of cancerous tissue, through administration of Auger-electron emitting radionucleoside analogs using high-flow microinfusion techniques (“convection-enhanced delivery”). Direct infusion under pressure, at flow rates in excess of at least about 0.5 microliters/min of the radionucleosides provides for their mass transport through tissue to a much higher degree than could be achieved by passive, unpressurized diffusion.Type: ApplicationFiled: March 19, 2008Publication date: June 9, 2011Applicant: Peak Biosciences Inc.Inventors: William D. Dalke, Michael J. Gerber, Kevin Lillehei, James E. Matsuura, Stephen L. Warren
-
Patent number: 7863047Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.Type: GrantFiled: April 25, 2008Date of Patent: January 4, 2011Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Patent number: 7825087Abstract: The present invention is directed to a composition comprising a nanoparticulate cyclosporine having improved bioavailability. The nanoparticulate cyclosporine particles of the composition have an effective average particle size of less than about 2000 nm in diameter and are useful in the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases. The invention also relates to a controlled release composition comprising a cyclosporine or a nanoparticulate cyclosporine that in operation delivers the drug in a pulsed or bimodal manner for the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases.Type: GrantFiled: April 12, 2006Date of Patent: November 2, 2010Assignee: Elan Pharma International LimitedInventors: Scott A. Jenkins, Gary Liversidge
-
Patent number: 7648695Abstract: New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues.Type: GrantFiled: July 6, 2001Date of Patent: January 19, 2010Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott
-
Patent number: 7625548Abstract: Liquid nanoscale particle precursor materials for generating nanoscale particles include at least one high volatility carrier and a second component. A nanoscale particle generating device generates nanoscale particles by passing a liquid nanoscale particle precursor material through a flow passage heated to convert the carrier into a vapor and the second component into nanoscale particles. The nanoscale particles preferably consist essentially of the second component and can consist essentially of dry, solid particles. The particle generator can be incorporated in a hand held inhaler, and can be delivered to a targeted portion of the lung using the inhaler. Composite controlled release particles of micron or nanoscale size can be produced by flowing a solution of medicament, control release agent and carrier liquid through a capillary heater.Type: GrantFiled: May 5, 2008Date of Patent: December 1, 2009Assignee: Philip Morris USA Inc.Inventors: Tung T. Nguyen, Nina Brown, Jui C. Lin, Stephen Pham, Kenneth A. Cox, Douglas D. McRae, Walter A. Nichols
-
Patent number: 7582279Abstract: A surface-modified lipoprotein-like oil-in-water emulsion useful as a blood-pool selective delivery vehicle for lipophilic imaging agents or lipophilic derivatives of water-soluble imaging agents. The blood-pool selective delivery vehicle remains in the blood for several hours, shows very little early hepatic sequestration, and is cleared from the blood within 24 hours. The mean diameter of the oil phase is less than 150 nm which minimizes sequestration by the reticuloendothelial system. The surface of the oil phase is modified with a polyethyl glycol-modified phospholipid to prevent normal interactions with the receptor sites of the hepatocytes.Type: GrantFiled: October 23, 2003Date of Patent: September 1, 2009Assignee: The Board of Regents of the University of MichiganInventors: Raymond E. Counsell, Marc A. Longino, Jamey P. Weichert
-
Patent number: 7553835Abstract: The subject matter relates to a topical, foamable composition including at least one antifungal agent, said composition characterised in that said at least one antifungal agent is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and in that it has a residual non-volatile component content of less than 25%. The subject matter furthermore relates to a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis by applying to the affected area of a patient requiring such treatment the antifungal composition.Type: GrantFiled: October 19, 1998Date of Patent: June 30, 2009Assignee: Stiefel Research Australia Pty LtdInventors: Greg Davey, Albert Zorko Abram
-
Patent number: 7541332Abstract: A reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered. Further, genes conferring resistance to the above compounds were identified and methods of screening for compounds that inhibit the activity of the proteins encoded by these genes were developed. Therefore, through the novel compounds, the present invention showed that antifungal agents having a novel mechanism, i.e. inhibiting the process that transports GPI-anchored proteins to the cell wall, could be achieved.Type: GrantFiled: April 21, 2006Date of Patent: June 2, 2009Assignee: Eisai R&D Management Co., Ltd.Inventors: Kappei Tsukahara, Katsura Hata, Koji Sagane, Kazutaka Nakamoto, Mamiko Tsuchiya, Naoaki Watanabe, Fuminori Ohba, Itaru Tsukada, Norihiro Ueda, Keigo Tanaka, Junko Kai
-
Patent number: 7531500Abstract: Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.Type: GrantFiled: November 28, 2006Date of Patent: May 12, 2009Assignee: The Regents of the University of CaliforniaInventors: Jay A. Nadel, Kiyoshi Takeyama
-
Patent number: 7521187Abstract: This invention relates generally to the freeze-drying of formulations comprising a polynucleotide, a block copolymer and a cationic surfactant. In the presence of a cryoprotectant or bulking agent, a formulation can be freeze-dried, whereby upon reconstitution of the dried formulation, the microparticles maintain their optimal size and aggregation or fusion is avoided.Type: GrantFiled: December 2, 2003Date of Patent: April 21, 2009Assignee: Vical IncorporatedInventor: Andrew Geall
-
Publication number: 20090072169Abstract: A cover for a syringe includes an elongated flexible envelope and an absorbent material. The elongated flexible envelope includes a body portion and a needle-receiving portion. The body portion has a first end that defines an opening and an opposite second end. The needle-receiving portion extends from the second end of the body portion and terminates in a distal end. The body portion and the needle-receiving portion define a cavity of sufficient size to allow the syringe to be placed therein. The cavity is in communication with the opening. The envelope is made of a material that is impervious to liquid. The absorbent material is disposed in the distal end of the needle-receiving portion.Type: ApplicationFiled: September 17, 2007Publication date: March 19, 2009Inventor: Perry Polsinelli
-
Publication number: 20080274044Abstract: There is disclosed an aerosol comprising droplets of an aqueous dispersion of nanoparticles, said nanoparticles comprising insoluble therapeutic or diagnostic agent particles having a surface modifier on the surface thereof. There is also disclosed a method for making the aerosol and methods for treatment and diagnosis using the aerosol.Type: ApplicationFiled: April 18, 2008Publication date: November 6, 2008Inventors: Ray W. Wood, Lan DeCastro, H. William Bosch
-
Patent number: 7402299Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.Type: GrantFiled: November 30, 2004Date of Patent: July 22, 2008Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Patent number: 7384971Abstract: New compositions are disclosed that comprise the phytochemical Diindolylmethane (DIM), as well as its precursor, Indole-3-carbinol (I3C), and cogener, 2-(Indol-3-ylmethyl)-3,3?diindolylmethane (LTr-1), acceptable carriers and/or excipients. These compositions are administered to prevent or reduce symptoms associated with mastalgia, endometriosis and HPV-related conditions including cervical dysplasia.Type: GrantFiled: July 9, 2003Date of Patent: June 10, 2008Assignee: BioResponse L.L.C.Inventor: Michael A. Zeligs
-
Patent number: 7384623Abstract: High energy phototherapeutic agents or radiosensitizer agents comprised of a halogenated xanthene, or other related agents that exhibit a preference for concentration in biologically sensitive structures in diseased tissue, and methods of treating and imaging using such radiosensitizer agents in such diseased tissue are described herein.Type: GrantFiled: August 25, 1999Date of Patent: June 10, 2008Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy Scott, John T. Smolik, Eric A. Wachter
-
Publication number: 20080127968Abstract: The present invention includes a method for delivering medications deeper into the lungs and to the medications' pulmonary targets, which include bronchioles and alveoli. A first particularly preferred embodiment of the invention describes the use of two steps for delivery of a medication. In a first step, an aerosolized therapeutic composition or medication is administered into a patient's respiratory tract, wherein the patient may be any animal or human subject. Following the first step, an aerosolized surfactant is administered into the patient's respiratory tract that facilitates delivery of the aerosolized medication of the first step to the medication's pulmonary target. Another embodiment of the present invention contemplates an apparatus for the delivery of an aerosolized surfactant used that facilitates delivery of previously inhaled aerosolized medication.Type: ApplicationFiled: October 26, 2007Publication date: June 5, 2008Applicant: Next Breath LLCInventors: SHAILAJA SOMARAJU, JULIE SUMAN
-
Patent number: 7358222Abstract: Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.Type: GrantFiled: February 7, 2003Date of Patent: April 15, 2008Assignee: The Regents of the University of CaliforniaInventors: Jay A. Nadel, Kiyoshi Takeyama
-
Publication number: 20080038190Abstract: In one embodiment, a composition comprises a microparticle including a radioactive isotope and an imageable element. In another embodiment, a method includes forming a microparticle including a target isotope and an enriched paramagnetic isotope, and transforming the target isotope into a radioactive isotope. In yet another embodiment, an apparatus includes an imaging system to image a subject; and a radioactive microparticle suitable for infusion into the subject for imaging by the imaging system and including an enriched paramagnetic isotope that is enriched to reduce generation of radioactive impurities while maintaining or improving imaging sensitivity.Type: ApplicationFiled: August 11, 2006Publication date: February 14, 2008Inventors: Thomas J. Simpson, Jim Hagerman
-
Publication number: 20070292344Abstract: The present disclosure provides a children's first aid kit suitable for treating minor scrapes and cuts. The compact kit is integral with a reusable cooling mechanism designed to provide a cooling sensation to the injured area. The kit is further integral with a supply of antiseptic medicine and bandages, and can be easily carried and made available in any situation.Type: ApplicationFiled: September 22, 2006Publication date: December 20, 2007Inventor: James W. Turner
-
Patent number: 7288243Abstract: The present invention provides a method of inhibiting growth of lung metastases in an individual comprising the steps of administering a dose of a lipid-drug enhancer liposomal complex and, in sequence, administering a dose of a lipid-anticancer drug liposomal complex. Furthermore, the lipid-drug enhancer liposomal complex may be administered in a continuing dose with the lipid-anticancer drug liposomal complex whereby both liposomal complexes are mixed in the nebulizer. Methods of inhibiting growth of lung metastases in an individual by the sequential administration via aerosolization of a dilauroylphosphatidylcholine-cyclosporin A liposomal complex and a dilauroylphosphatidylcholine-paclitaxel liposomal complex are also provided.Type: GrantFiled: May 16, 2003Date of Patent: October 30, 2007Assignee: Research Development FoundationInventors: J. Vernon Knight, J. Clifford Waldrep, Nadezhda Koshkina
-
Patent number: 7250152Abstract: A process for the co-precipitation of a substance with a stabilizer therefor, by a gas anti solvent process comprising introducing into a particle formation vessel a supercritical fluid pure or mixed with a modifier; and a solution comprising said substance and said stabilizer dissolved in a solvent; so as said solvent is extracted from the solution by said supercritical fluid and co-precipitation of the substance and stabilizer occurs. The process may be carried out using an apparatus, for example, shown in FIG. 1, comprising a particle formation vessel (22) and a nozzle (27) having a central orifice (39) serving to introduce a solution of the substance and a plurality of outer orifices (41) serving to carry a flow of supercritical fluid into the particle formation vessel (22), such that the solvent is extracted from the solution by the supercritical fluid and precipitation of micron sized particles of the substance/stabilizer occurs.Type: GrantFiled: October 21, 2002Date of Patent: July 31, 2007Assignee: Dompé pha.r.ma S.p.A.Inventors: Marco Gentile, Cesare Di Palma, Maria Candida Cesta
-
Patent number: 7235264Abstract: Xenon or xenon-containing gases and, where appropriate, an NO source are employed as medicament for cerebral protection. Cerebral protection is defined as reducing or preventing impairments of cerebral function of various causes, but especially secondary to perfusion impairments of unclear etiology. The medicament can be used for cerebral protection for the prophylaxis of impairments of cerebral perfusion and for therapy after cerebral disorders have occurred, irrespective of the cause (e.g. cognitive, sensory or motor in nature).Type: GrantFiled: June 12, 2003Date of Patent: June 26, 2007Assignee: Air Liquide Deutschland GmbHInventors: Peter Neu, Carsten Pilger, Matthias Reyle-Hahn
-
Patent number: 7217409Abstract: A method for treating respiratory disorders comprises administering to a patient a pharmaceutical aerosol formulation comprising: (i) a compound of formula (I) or a salt or solvate thereof, wherein: n represents an integer 1 to 6; N represents an integer 1 to 15; R1 represents —(CO)xC1-9 alkyl or —(CO)xC1-9 fluoroalkyl, which fluoroalkyl moiety contains at least 1 fluorine atom and not more than 3 consecutive perfluorocarbon atoms wherein x represents 0 or 1; and R2 and R3 independently represent C1-3alkyl or hydrogen, (ii) at least one medicament, and (iii) at least one propellant.Type: GrantFiled: September 21, 2001Date of Patent: May 15, 2007Assignee: SmithKline Beecham CorporationInventors: Brian Edgar Looker, Christopher James Lunniss, Alison Judith Redgrave, Derek Peter Reynolds
-
Patent number: 7150888Abstract: Strong vapors from eucalyptus oil and tea tree oil are inhaled periodically to prevent respiratory system diseases including colds, flus, pneumonia, tuberculosis, and opportunistic infections in individuals having cystic fibrosis. Apparatus for the periodic inhalation of strong vapors from eucalyptus oil and tea tree oil are provided.Type: GrantFiled: September 9, 2002Date of Patent: December 19, 2006Assignee: Inhalation, Inc.Inventors: William Banning Vail, III, Marilyn L. Vail
-
Patent number: 7048953Abstract: Concentrated vapors from botanical essential oils are inhaled to prevent, treat and cure infections of the respiratory pathogens causing Severe Acute Respiratory Syndrome (“SARS”). These vapors are inhaled as a practical method to reduce the risks of infection by the pathogens causing SARS in crowded public places. These vapors are also inhaled as a practical method to reduce the risks of infection by unknown, and unpredictable, respiratory pathogens that may be present in public places. The essential oils have antiseptic properties, are safe to inhale, and include, but are not limited to, the essential oils from Eucalyptus globulus, Melaleuca alternifolia, Eucalyptus citriodora, and Eucalyptus radiata. Convenient hand-held inhaler apparatus are provided for the inhalation of concentrated vapors from the antiseptic essential oils and other substances. The antiseptic essential oils have selected antiviral, antibacterial, and antifungal properties.Type: GrantFiled: May 2, 2003Date of Patent: May 23, 2006Assignee: Inhalation, Inc.Inventors: William Banning Vail, III, Marilyn L. Vail
-
Patent number: 6977068Abstract: A method for the detection of fibrin in a source, in particular the in vivo detection of a fibrin in a patient, the method comprising supplying to the source or patient an amount of a detectable reagent comprising a plurality of discrete particles, each of the particles comprising a plurality of layers of carbon and being capable of binding to fibrin; and detecting the presence of the particles in the source. The particles may also comprise a detectable marker encased in said plurality of layers of carbon, the presence of said marker being capable of detection in said source.Type: GrantFiled: July 23, 1998Date of Patent: December 20, 2005Assignee: The Australian National UniversityInventors: Chenicheri H. Nair, Elena A. Shats, William M. Burch, Rodney J. Browitt, Timothy J. Senden
-
Patent number: 6635234Abstract: Processes for the preparation, prepared solutions, and the use of radium-223 for the treatment of calcified tumors, bone tumors, treatment of bones, bone surfaces and soft tissues is described.Type: GrantFiled: January 3, 2000Date of Patent: October 21, 2003Assignee: Anticancer Therapeutic Inventions ASInventors: Roy H. Larsen, Gjermund Henriksen, Øyvind S. Bruland
-
Patent number: RE40300Abstract: The present invention provides a method of increasing the deposition of aerosolized drug in the respiratory tract of an individual or animal, comprising the step of administering said aerosolized drug in an air mixture containing up to about 10% carbon dioxide gas.Type: GrantFiled: August 26, 2004Date of Patent: May 6, 2008Assignee: Research Development FoundationInventors: J. Clifford Waldrep, J. Vernon Knight, Nadezhda Koshkina
-
Patent number: RE38407Abstract: Liposome-encapsulated opioid analgesic agents delivered by the pulmonary route provide local, or systemic analgesia superior to that produced by the solution form of these agents administered by parentral (intravenous, intramuscular, or subcutaneous injection) or oral routes.Type: GrantFiled: June 14, 2001Date of Patent: January 27, 2004Assignee: Delex Therapeutics Inc.Inventors: Michael Mezel, Orlando Hung